Top-Rated Dividend StocksTop-Rated DividendNASDAQ:RPRX Royalty Pharma (RPRX) Stock Forecast, Price & News $32.51 +0.13 (+0.40%) (As of 04:00 PM ET) Add Compare Share Share Today's Range$32.17▼$32.7750-Day Range$32.22▼$37.3952-Week Range$32.02▼$44.66Volume2.80 million shsAverage Volume1.86 million shsMarket Capitalization$19.74 billionP/E Ratio59.11Dividend Yield2.46%Price Target$54.00 ProfileProfileAnalyst RatingsChartCompetitorsDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Royalty Pharma MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside67.2% Upside$54.00 Price TargetShort InterestHealthy1.92% of Float Sold ShortDividend StrengthWeakBased on Four FactorsSustainability-2.25Upright™ Environmental ScoreNews Sentiment0.39Based on 9 Articles This WeekInsider TradingSelling Shares$61.51 M Sold Last QuarterProj. Earnings Growth-6.46%From $4.18 to $3.91 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.3.30 out of 5 starsFinance Sector35th out of 905 stocksPharmaceutical Preparations Industry3rd out of 494 stocks 3.5 Analyst's Opinion Consensus RatingRoyalty Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $54.00, Royalty Pharma has a forecasted upside of 67.2% from its current price of $32.29.Amount of Analyst CoverageRoyalty Pharma has only been the subject of 2 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.92% of the float of Royalty Pharma has been sold short.Short Interest Ratio / Days to CoverRoyalty Pharma has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Royalty Pharma has recently decreased by 7.35%, indicating that investor sentiment is improving significantly. Previous Next 1.7 Dividend Strength Dividend YieldRoyalty Pharma pays a meaningful dividend of 2.47%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthRoyalty Pharma has only been increasing its dividend for 3 years.Dividend CoverageThe dividend payout ratio of Royalty Pharma is 145.45%. Payout ratios above 75% are not desirable because they may not be sustainable.Dividend SustainabilityBased on earnings estimates, Royalty Pharma will have a dividend payout ratio of 20.46% next year. This indicates that Royalty Pharma will be able to sustain or increase its dividend. Previous Next 3.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRoyalty Pharma has received a 47.64% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Rotavirus vaccine", "HIV medication", "Breast cancer medication", "Prostate cancer medication", "Rheumatoid arthritis medication", and "Multiple myeloma medication" products. See details.Environmental SustainabilityThe Environmental Impact score for Royalty Pharma is -2.25. Previous Next 3.0 News and Social Media Coverage News SentimentRoyalty Pharma has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Finance companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Royalty Pharma this week, compared to 3 articles on an average week.Search Interest30 people have searched for RPRX on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days.MarketBeat Follows6 people have added Royalty Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Royalty Pharma insiders have sold 501.74% more of their company's stock than they have bought. Specifically, they have bought $10,221,725.00 in company stock and sold $61,507,766.00 in company stock.Percentage Held by Insiders24.86% of the stock of Royalty Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions55.36% of the stock of Royalty Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Royalty Pharma are expected to decrease by -6.46% in the coming year, from $4.18 to $3.91 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Royalty Pharma is 58.71, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 128.48.Price to Earnings Ratio vs. SectorThe P/E ratio of Royalty Pharma is 58.71, which means that it is trading at a less expensive P/E ratio than the Finance sector average P/E ratio of about 156.56.Price to Earnings Growth RatioRoyalty Pharma has a PEG Ratio of 0.64. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioRoyalty Pharma has a P/B Ratio of 2.06. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Royalty Pharma (NASDAQ:RPRX) StockRoyalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.Read More Receive RPRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Royalty Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address RPRX Stock News HeadlinesMay 28, 2023 | americanbankingnews.comRoyalty Pharma (NASDAQ:RPRX) Stock Rating Upgraded by StockNews.comMay 25, 2023 | benzinga.comCEO of Royalty Pharma Makes $4.84M BuyMay 30, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.May 25, 2023 | americanbankingnews.comRoyalty Pharma (NASDAQ:RPRX) Reaches New 12-Month Low After Insider SellingMay 24, 2023 | americanbankingnews.comRoyalty Pharma plc (NASDAQ:RPRX) Director Rory B. Riggs Sells 1,750,000 SharesMay 24, 2023 | americanbankingnews.comRoyalty Pharma plc (NASDAQ:RPRX) Given Consensus Recommendation of "Moderate Buy" by AnalystsMay 18, 2023 | benzinga.comRoyalty Pharma CEO Makes $7.68M Stock PurchaseMay 12, 2023 | americanbankingnews.comRoyalty Pharma (NASDAQ:RPRX) Lowered to "Hold" at StockNews.comMay 30, 2023 | Behind the Markets (Ad)"Chilling War Games Show US Forces Crushed" – FOX NEWS=== BREAKING === "Chilling War Games Show US Forces Crushed" - FOX NEWS After losing to China in repeated war games, U.S. military to spend billions on new "living missile" for armed forces. Investors stand to reap 35,960% on shares of small defense contractor that makes powerful new weapon. Get the name of the stock here >>>May 12, 2023 | msn.comMorgan Stanley Maintains Royalty Pharma plc - (RPRX) Overweight RecommendationMay 11, 2023 | finance.yahoo.comRoyalty Pharma's (NASDAQ:RPRX) Upcoming Dividend Will Be Larger Than Last Year'sMay 9, 2023 | finance.yahoo.comRoyalty Pharma (RPRX) Q1 Earnings and Revenues Top EstimatesMay 9, 2023 | msn.comRoyalty Pharma (RPRX) Q1 Earnings: Taking a Look at Key Metrics Versus EstimatesMay 9, 2023 | seekingalpha.comRoyalty Pharma plc 2023 Q1 - Results - Earnings Call PresentationMay 9, 2023 | finanznachrichten.deRoyalty Pharma plc: Royalty Pharma Reports First Quarter 2023 ResultsMay 9, 2023 | finance.yahoo.comRoyalty Pharma Reports First Quarter 2023 ResultsMay 8, 2023 | msn.comEarnings Outlook For Royalty PharmaMay 8, 2023 | msn.comRoyalty Pharma Q1 2023 Earnings PreviewMay 8, 2023 | americanbankingnews.comRoyalty Pharma (RPRX) to Release Quarterly Earnings on TuesdayMay 3, 2023 | finance.yahoo.comRoyalty Pharma To Present At The BofA Securities 2023 Health Care ConferenceApril 29, 2023 | americanbankingnews.comBrokerages Set Royalty Pharma plc (NASDAQ:RPRX) Target Price at $54.14April 20, 2023 | finance.yahoo.comRoyalty Pharma (NASDAQ:RPRX) Is Increasing Its Dividend To $0.20April 19, 2023 | americanbankingnews.comRoyalty Pharma plc (RPRX) To Go Ex-Dividend on May 18thApril 19, 2023 | msn.comRoyalty Pharma (RPRX) Declares $0.20 DividendApril 17, 2023 | finance.yahoo.comRoyalty Pharma Declares Second Quarter 2023 DividendApril 13, 2023 | finance.yahoo.comRoyalty Pharma to Announce First Quarter 2023 Financial Results on May 9, 2023April 11, 2023 | msn.comMorgan Stanley Maintains Royalty Pharma (RPRX) Overweight RecommendationSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive RPRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Royalty Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address RPRX Company Calendar Last Earnings11/10/2021Ex-Dividend for 3/15 Dividend2/15/2023Dividend Payable3/15/2023Ex-Dividend for 6/15 Dividend5/18/2023Today5/30/2023Dividend Payable6/15/2023Next Earnings (Estimated)8/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorFinance Current SymbolNASDAQ:RPRX CUSIP76028H20 CIK897075 Webwww.royaltypharma.com Phone212-883-0200FaxN/AEmployees51Year Founded1996Price Target and Rating Average Stock Price Forecast$54.00 High Stock Price Forecast$60.00 Low Stock Price Forecast$48.00 Forecasted Upside/Downside+66.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)$0.55 Trailing P/E Ratio58.82 Forward P/E Ratio7.74 P/E Growth0.64Net Income$42.83 million Net Margins14.12% Pretax Margin25.90% Return on Equity28.30% Return on Assets16.40% Debt Debt-to-Equity Ratio0.62 Current Ratio2.36 Quick Ratio2.36 Sales & Book Value Annual Sales$2.36 billion Price / Sales8.33 Cash Flow$3.72 per share Price / Cash Flow8.69 Book Value$15.69 per share Price / Book2.06Miscellaneous Outstanding Shares607,138,000Free Float456,203,000Market Cap$19.64 billion OptionableNot Optionable Beta0.42 Social Links Key ExecutivesMr. Pablo Gerardo Legorreta (Age 58)Founder, Chairman & CEO Comp: $49.51MMr. Terrance P. CoyneExec. VP & CFOMr. George Wingate Lloyd (Age 63)Exec. VP of Investments & Chief Legal Officer Comp: $3.9MMr. Christopher Hite (Age 55)Vice Chairman & Exec. VP Comp: $4.01MDr. Marshall Urist M.D.Ph.D., Exec. VP and Head of Research & InvestmentsMr. Arthur R. McGivern J.D.Exec. VP of Investments & Gen. CounselMs. Kristin StaffordSr. VP & Chief Accounting OfficerDr. James Folmar Reddoch Ph.D. (Age 52)Exec. VP of Investments & Chief Scientific Officer Mr. George Grofik C.F.A.CPA, Sr. VP and Head of Investor Relations & CommunicationsMs. Alessandra SassunVP & Head of Human CapitalMore ExecutivesKey CompetitorsExtra Space StorageNYSE:EXRORIXNYSE:IXInvitation HomesNYSE:INVHAlexandria Real Estate EquitiesNYSE:AREM&T BankNYSE:MTBView All CompetitorsInsiders & InstitutionsProShare Advisors LLCSold 11,377 shares on 5/26/2023Ownership: 0.005%Pablo G LegorretaBought 150,000 shares on 5/24/2023Total: $4.84 M ($32.25/share)Toroso Investments LLCBought 4,468 shares on 5/23/2023Ownership: 0.009%Ameriprise Financial Inc.Bought 98,288 shares on 5/22/2023Ownership: 0.245%Rory B RiggsSold 1,750,000 sharesTotal: $57.44 M ($32.82/share)View All Insider TransactionsView All Institutional Transactions RPRX Stock - Frequently Asked Questions Should I buy or sell Royalty Pharma stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Royalty Pharma in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RPRX shares. View RPRX analyst ratings or view top-rated stocks. What is Royalty Pharma's stock price forecast for 2023? 4 brokerages have issued 1-year target prices for Royalty Pharma's stock. Their RPRX share price forecasts range from $48.00 to $60.00. On average, they predict the company's share price to reach $54.00 in the next year. This suggests a possible upside of 66.9% from the stock's current price. View analysts price targets for RPRX or view top-rated stocks among Wall Street analysts. How have RPRX shares performed in 2023? Royalty Pharma's stock was trading at $39.52 at the beginning of the year. Since then, RPRX stock has decreased by 18.1% and is now trading at $32.35. View the best growth stocks for 2023 here. When is Royalty Pharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023. View our RPRX earnings forecast. How were Royalty Pharma's earnings last quarter? Royalty Pharma plc (NASDAQ:RPRX) released its earnings results on Wednesday, November, 10th. The biopharmaceutical company reported $0.17 earnings per share for the quarter, missing analysts' consensus estimates of $0.69 by $0.52. The biopharmaceutical company had revenue of $587 million for the quarter, compared to analyst estimates of $568.92 million. Royalty Pharma had a net margin of 14.12% and a trailing twelve-month return on equity of 28.30%. During the same quarter last year, the company earned $0.48 earnings per share. How often does Royalty Pharma pay dividends? What is the dividend yield for Royalty Pharma? Royalty Pharma declared a quarterly dividend on Monday, April 17th. Investors of record on Friday, May 19th will be paid a dividend of $0.20 per share on Thursday, June 15th. This represents a $0.80 dividend on an annualized basis and a yield of 2.47%. The ex-dividend date is Thursday, May 18th. Read our dividend analysis for RPRX. What ETFs hold Royalty Pharma's stock? ETFs with the largest weight of Royalty Pharma (NASDAQ:RPRX) stock in their portfolio include iShares U.S. Pharmaceuticals ETF (IHE), SPDR S&P Pharmaceuticals ETF (XPH), Formidable ETF (FORH), Renaissance IPO ETF (IPO), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), VictoryShares Nasdaq Next 50 ETF (QQQN), Invesco Zacks Mid-Cap ETF (CZA) and Invesco Nasdaq Biotechnology ETF (IBBQ). Is Royalty Pharma a good dividend stock? Royalty Pharma (NASDAQ:RPRX) pays an annual dividend of $0.80 per share and currently has a dividend yield of 2.47%. The company has been increasing its dividend for 3 consecutive year(s), indicating that it does not yet have a strong track record of dividend growth. The dividend payout ratio is 145.45%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, RPRX will have a dividend payout ratio of 20.46% next year. This indicates that the company will be able to sustain or increase its dividend. Read our dividend analysis for RPRX. What other stocks do shareholders of Royalty Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Royalty Pharma investors own include Twitter (TWTR), Bausch Health Companies (BHC), NVIDIA (NVDA), (RLYP) (RLYP), Aeterna Zentaris (AEZS), Advanced Micro Devices (AMD), Netflix (NFLX), QUALCOMM (QCOM), Salesforce (CRM) and Twilio (TWLO). When did Royalty Pharma IPO? (RPRX) raised $1.9 billion in an initial public offering on Tuesday, June 16th 2020. The company issued 70,000,000 shares at a price of $25.00-$28.00 per share. J.P. Morgan, Morgan Stanley, BofA Securities, Goldman Sachs, Citigroup and UBS Investment Bank acted as the underwriters for the IPO and Evercore ISI, Cowen and SunTrust Robinson Humphrey were co-managers. What is Royalty Pharma's stock symbol? Royalty Pharma trades on the NASDAQ under the ticker symbol "RPRX." Who are Royalty Pharma's major shareholders? Royalty Pharma's stock is owned by many different retail and institutional investors. Top institutional shareholders include FMR LLC (6.58%), BlackRock Inc. (3.27%), Baillie Gifford & Co. (3.12%), JPMorgan Chase & Co. (1.43%), State Street Corp (1.37%) and Geode Capital Management LLC (0.99%). Insiders that own company stock include 1978 Sicaf Sif SA - Gg St Gg, 1978 Sicaf Sif SA Gg, Adage Capital Partners Gp, LL, George W Lloyd, Henry A Fernandez, James F Reddoch, James F Reddoch, Mario Germano Giuliani, Marshall Urist, Pablo G Legorreta, Rory B Riggs, Sanjay Kumar Singh, Scientific Corp Boston, Terrance P Coyne and William E Ford. View institutional ownership trends. How do I buy shares of Royalty Pharma? Shares of RPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Royalty Pharma's stock price today? One share of RPRX stock can currently be purchased for approximately $32.35. How much money does Royalty Pharma make? Royalty Pharma (NASDAQ:RPRX) has a market capitalization of $19.64 billion and generates $2.36 billion in revenue each year. The biopharmaceutical company earns $42.83 million in net income (profit) each year or $0.55 on an earnings per share basis. How can I contact Royalty Pharma? Royalty Pharma's mailing address is 110 E 59th Street, New York NY, 10022. The official website for the company is www.royaltypharma.com. The biopharmaceutical company can be reached via phone at 212-883-0200 or via email at ir@royaltypharma.com. This page (NASDAQ:RPRX) was last updated on 5/30/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Royalty Pharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.